Please ensure Javascript is enabled for purposes of website accessibility

Why Shares in DBV Technologies SA Are Soaring 10% Today

By Todd Campbell - Jul 15, 2015 at 1:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

DBV Technologies is raising more than $244 million to develop therapies for peanut and milk allergies.

What: After pricing shares of its equity offering at $34, shares in DBV Technologies SA (DBVT 3.94%) jumped by 10% earlier today.

So what: Since developing new drugs is incedibly expensive, it's not uncommon for clinical stage companies like DBV Technologies to tap equity investors for funding.

In this case, the France-based DBV Technologies plans to sell 3.6 million American Depository Receipts, which at $34 per share should generate $244.8 million in proceeds, before deducting fees, commissions, and other discounts.

That money will be used to advance clinical studies of immunotherapy products that can be applied directly on a patient's skin to treat common food allergies.

DBV Technologies is currently developing Viaskin Peanut and Viaskin Milk as topical thereapies for peanut and milk allergies, respectively.

Viaskin Peanut is currently in a phase 2b follow-up study that is assessing its efficacy and safety across 170 patients with peanut allergies, while Viaskin Milk is about to enter the second part of a phase 1 study.

Now what: DBV Technologies' potential to revolutionize food allergies is massive. According to studies, more than 125,000 people visit emergency rooms in America annually because of food allergies, and roughly 3 million Americans are thought to be allergic to peanuts and/or nuts. As many as twice that number may suffer from milk allergies.

Because no therapies are currently approved for these allergies and they're widespread, some enthusiasm is likely warranted. However, investors should remember that DBV Technologies is still early in the development of these therapies and that means that a lot can still go wrong and derail its shares. Regardless, the company's intriguing enough for me to add it to my watch list.

Todd Campbell has no position in any stocks mentioned. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
DBVT
$2.64 (3.94%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.